Welcome to our dedicated page for ERPY news (Ticker: ERPY), a resource for investors and traders seeking the latest updates and insights on ERPY stock.
ERP Technologies (ERPY) provides investors and business professionals with essential updates through this comprehensive news hub. Track official announcements including financial disclosures, product enhancements, and strategic collaborations that shape this ERP innovator's market position.
Access timely updates on earnings reports, operational milestones, and partnership developments like ERPY's collaboration with Vetophage. Our curated feed ensures you never miss critical information about software innovations or industry leadership changes.
Discover verified information about enterprise solution developments directly from primary sources. This resource serves both technical professionals seeking product details and investors monitoring organizational growth patterns.
Bookmark this page for streamlined access to ERPY's evolving business narrative. Regular updates ensure you maintain informed perspectives on this dynamic player in enterprise resource planning technology.
ERYTECH Pharma is hosting a key opinion leader webinar on its product candidate eryaspase for treating pancreatic cancer on September 1, 2021. The webinar will feature insights from experts including Dr. Manuel Hidalgo and Dr. Marcus Noel, who will discuss ongoing clinical trials of eryaspase in both second-line and first-line settings. The Phase 3 TRYbeCA-1 trial has enrolled 512 patients, with final results expected in Q4 2021. Eryaspase has received Fast Track designation from the FDA and orphan drug status for pancreatic cancer and ALL.
As of July 30, 2021, the total number of shares composing the share capital of the company is 27,320,457, with total gross voting rights at 28,844,656 and net voting rights at 28,842,156. This includes changes from previous months where shares have increased from 21,646,489 in April to the current total, reflecting a positive trend in share capital. This report complies with Article 223-16 of the French regulatory framework, ensuring transparency in shareholders' rights.
ERYTECH Pharma announced that the U.S. FDA has granted Fast Track designation for its lead product, eryaspase, for patients with acute lymphoblastic leukemia (ALL) who experience hypersensitivity reactions to pegylated asparaginase. This designation highlights the pressing need for alternative treatment options, as up to 30% of patients face hypersensitivity issues. The company plans to submit a Biologics License Application for this indication in Q4 2021.
ERYTECH Pharma will participate in the BTIG Virtual Biotechnology Conference on August 9, 2021. CEO Gil Beyen will engage in a fireside chat at 9:30 AM ET and will also hold one-on-one meetings. The company is focused on developing innovative therapies utilizing its ERYCAPS® platform for severe cancers and orphan diseases. Its leading product candidate, eryaspase, targets altered cancer metabolism and is currently in Phase 3 for second-line pancreatic cancer and Phase 2 for triple-negative breast cancer. Eryaspase has received FDA Fast Track designation.
ERYTECH has confirmed its plans to submit a Biologics License Application (BLA) for eryaspase aimed at treating acute lymphoblastic leukemia (ALL) patients with hypersensitivity to asparaginase therapy. Following a pre-BLA meeting with the U.S. FDA, the company received crucial feedback that could support its submission by the end of 2021. This follows positive Phase 2 trial results presented at the 2020 ASH Annual Meeting. The BLA submission represents a critical milestone for ERYTECH as it advances eryaspase's development.
The press release provides essential monthly information about the total number of voting rights and shares in circulation as of June 30, 2021. The total shares composing the capital stand at 26,412,389. The gross voting rights total 27,934,088, while the net voting rights amount to 27,931,588. These figures are crucial as they reflect the company's corporate governance and voting power available for shareholders. The document complies with Article 223-16 of the French Financial Markets Authority regulations.
ERYTECH Pharma held its 2021 Annual General Meeting in Lyon on June 25, 2021, where shareholders approved all resolutions proposed by the Board of Directors. Key approvals included the annual financial statements for 2020, the allocation of financial results, executive compensation policies, and new share option plans. The meeting also authorized the Board to issue new shares and share subscription options. ERYTECH is focused on developing eryaspase, its lead product for treating difficult cancers, which is currently in various stages of clinical development.
The press release provides monthly updates on the total number of shares and voting rights as of May 31, 2021, in compliance with the French regulations. As of this date, the total number of shares composing the share capital is noted as 26,048,225, with 27,569,797 gross voting rights and 27,567,297 net voting rights. Previous months' figures reflect an increase in the total shares and voting rights, suggesting a positive trend in shareholder engagement. The release serves to inform investors and the market about the company's share structure.
ERYTECH Pharma (Nasdaq & Euronext: ERYP) will participate in several virtual investor conferences in June 2021. The Jefferies Virtual Healthcare Conference is scheduled from June 1-4, featuring CEO Gil Beyen in a fireside chat on June 4 at 10 AM ET. The JMP Securities Life Sciences Conference will take place on June 16-17, with a presentation by Beyen on June 16 at 2 PM ET. Additionally, the Spring European Midcap Event is set for June 24-25, where Beyen and CFO Eric Soyer will hold one-on-one meetings.
Erytech Pharma has announced its Combined Shareholders’ Meeting scheduled for June 25, 2021, to be held in a closed session at 2 PM CET. Due to recent French legislation, no shareholders will be present in person, and they are encouraged to vote remotely prior to the meeting. Voting procedures have been outlined, including mail and online options through the VOTACCESS platform, available from June 7 to June 24. Shareholders can follow the meeting through a live web conference, with instructions for submitting questions provided. All relevant documents are accessible on the company's website.
